Financial Analysis: Capnia (SLNO) versus Its Competitors

Capnia (NASDAQ: SLNO) is one of 81 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its rivals? We will compare Capnia to similar businesses based on the strength of its institutional ownership, risk, earnings, dividends, profitability, valuation and analyst recommendations.

Risk & Volatility

Capnia has a beta of 6.04, indicating that its stock price is 504% more volatile than the S&P 500. Comparatively, Capnia’s rivals have a beta of 0.93, indicating that their average stock price is 7% less volatile than the S&P 500.


This table compares Capnia and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Capnia -1,389.76% -54.11% -46.95%
Capnia Competitors -423.11% -40.64% -10.96%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Capnia and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capnia 0 0 1 0 3.00
Capnia Competitors 211 1250 2717 95 2.63

Capnia currently has a consensus price target of $25.00, suggesting a potential upside of 1,685.71%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 4.19%. Given Capnia’s stronger consensus rating and higher probable upside, analysts plainly believe Capnia is more favorable than its rivals.

Institutional & Insider Ownership

65.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 69.8% of Capnia shares are owned by company insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Capnia and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Capnia $1.45 million -$12.06 million -0.68
Capnia Competitors $975.11 million $120.37 million 219.16

Capnia’s rivals have higher revenue and earnings than Capnia. Capnia is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


Capnia rivals beat Capnia on 7 of the 12 factors compared.

Capnia Company Profile

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Receive News & Ratings for Capnia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capnia Inc. and related companies with's FREE daily email newsletter.

Leave a Reply